secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001493152-25-007942
Event type: other_material
Sentiment:  positive
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics shareholders approve all five proposals at 2024 annual meeting
--------------------------------------------------------------------------------

- Elected Garo H. Armen and Brian J. Corvese as Class III directors with ~1.87M and ~1.85M for votes.
- Approved repricing of outstanding stock options: 1,803,833 for, 184,143 against, 70,373 abstain.
- Ratified MaloneBailey LLP as auditor for FY2024: 3,492,771 for, 81,987 against, 72,564 abstain.
- Approved issuance of common stock warrant shares from Oct 2024 agreements: 1,928,277 for, 58,942 against.
- Approved amendment to 2016 Equity Plan allowing option repricing without shareholder approval: 1,803,817 for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315225007942/0001493152-25-007942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315225007942/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-007942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer